ASCO/EHA 2024 Myeloma Highlights | Ajai Chari, MD | EHA 2024

ASCO/EHA 2024 Myeloma Highlights | Ajai Chari, MD | EHA 2024
Phase I Study Findings: anitocabtagene autoleucel for RRMM treatment | Binod Dhakal, MD | EHA 2024
Real-World Schedule De-escalation of Teclistamab in Patients with RRMM | Carlyn Tan, MD | EHA 2024
Phase 1b-2 Dose Escalation Study Sonrotoclax + Dexamethasone | Binod Dhakal, MD | EHA 2024
CARTITUDE-4 Subgroup Analysis of Functional High-Risk Patients | Luciano Costa, MD | EHA 2024
Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024
MAJESTIC-1 Study - A Subgroup Analysis of High-risk Patients | Luciano Costa, MD | EHA2024
ASCO/EHA Myeloma Updates 2024 | Claudio Cerchione, MD | EHA 2024
The Role of Combination FDG PET Plus Whole Body MRI for Staging | Claudio Cerchione, MD | EHA 2024